A Novel Geiparvarin Analogue Possessing a Fluorinated Segment

Claire Amato; Patrick Calas

doi:10.1055/s-2003-42446

PAPER

A Novel Geiparvarin Analogue Possessing a Fluorinated Segment

Claire Amato, Patrick Calas*
Laboratoire Organisation moléculaire, évolution et matériaux fluorés, UMR CNRS 5073, Université de Montpellier II, CC 17, Place E. Bataillon, 34095 Montpellier Cedex 05, France
Fax: +33(4)67631046; e-Mail: patrick.calas@univ-montp2.fr;

Abstract

All articles of this category

Abstract

Starting from the 4-(ω-iodoperfluorobutyl)-2-methylbut-3-yn-2-ol, the 5-(ω-iodoperfluoropropyl)furan-3(2H)-one is formed in one step under the Rupe conditions (reflux with formic acid, yield 93%). This compound is added to 2-methylbut-3-yn-2-ol through a radical chain process, using the Huang system (Na₂S₂O₄-NaHCO₃, MeCN-H₂O), yielding the expected adduct (47%), the hydrodeiodinated equivalent compound (35%) and a new spiro compound containing a partly fluorinated ring (18%). This latter compound may result from an interesting annulation process. The iodo adduct is hydrodeiodinated (Zn-AcOH-EtOH, final yield 82%) and added to umbelliferone through Mitsunobu etherification (PPh₃-DIAD-THF) yielding (45%) the expected Geiparvarin analogue possessing a fluorinated segment

Key words

Geiparvarin - antitumour agents - fluorine - furans - annulations - spiro compounds - DNA

Full Text

References

1a Curran DP. Singleton DH. Tetrahedron Lett. 1983, 24: 2079

1b Wolf S. Agosta WC. Tetrahedron Lett. 1985, 26: 703

1c Saimoto H. Hiyama T. Nosaki H. J. Am. Chem. Soc. 1981, 103: 4975

1d Jackson RFW. Raphael RA. J. Chem. Soc., Perkin Trans. 1 1984, 535

2 Kupchan SM. Sigel CW. Matz MJ. Gilmore CJ. Bryan RF. J. Am. Chem. Soc. 1976, 98: 2295

3a Chen K.-M. Joullié MM. Tetrahedron Lett. 1984, 25: 393

3b Sakai T. Ito H. Yamawaki A. Takeda A. Tetrahedron Lett. 1984, 25: 2987

3c Baraldi PG. Barco A. Benetti S. Guarneri M. Manfredini S. Pollini GP. Simoni D. Tetrahedron Lett. 1985, 26: 5319

3d Kang SH. Hong CY. Tetrahedron Lett. 1987, 28: 675

3e Tabrizi MA. Baraldi PG. Guarneri M. Manfredi S. Pollini GP. Simoni D. Tetrahedron Lett. 1991, 32: 683

3f Smith AB. Jerris PJ. Tetrahedron Lett. 1980, 21: 711

3g Jerris PJ. Smith AB. J. Org. Chem. 1981, 46: 577

3h Baraldi PG. Barco A. Benetti S. Casolari A. Manfredini S. Pollini GP. Simoni D. Tetrahedron Lett. 1988, 44: 1267

3i Villemin D. Jaffrès P.-A. Hassemi M. Tetrahedron Lett. 1997, 38: 537

4a Baraldi PG. Manfredini S. Simoni D. Tabrizi MA. Balzarini J. De Clercq E. J. Med. Chem. 1992, 35: 1877

4b Manfredini S. Baraldi PG. Guarneri M. Simoni D. Balzarini J. De Clercq E. J. Med. Chem. 1994, 37: 2401

4c Miglietta A. Bocca C. Rampa A. Bisi A. Gabriel L. Anti-Cancer Drug Design 1997, 12: 607

4d Bocca C. Gabriel L. Miglietta A. Chem.-Biol. Interact. 2001, 137: 285

4e Miglietta A. Bocca C. Gabriel L. Rampa A. Bisi A. Valentini P. Cell Biochem. Funct. 2001, 19: 181

4f Carotti A. Carrieri A. Chimichi S. Boccalini M. Cosimelli B. Gnerre C. Carotti A. Carrupt P.-A. Testa B. Bioorg. Med. Chem. Lett. 2002, 12: 3551

4g Chimichi S. Boccalini M. Cosimelli B. Viola G. Vedaldi D. Dall"acqua F. Tetrahedron Lett. 2002, 43: 7473

4h Chimichi S. Boccalini M. Cosimelli B. Tetrahedron 2002, 58: 4851

5 Amato C. Naud C. Calas P. Commeyras A. J. Fluorine Chem. 2002, 113: 55

6 Gomez L. Calas P. Commeyras A. J. Chem. Soc., Chem. Commun. 1985, 1493

7 Hasbrouck RW. Anderson Kiessling AD. J. Org. Chem. 1973, 38: 2103

8 Huang WY. J. Fluorine Chem. 1992, 58: 1

9 Requirand N. Blancou H. Commeyras A. Bull. Soc. Chim. Fr. 1993, 130: 798

10 Reisch J. Voerste AAW. J. Chem. Soc., Perkin Trans. 1 1994, 3251